| __timestamp | Takeda Pharmaceutical Company Limited | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 520990000000 | 125883000 |
| Thursday, January 1, 2015 | 535405000000 | 69036000 |
| Friday, January 1, 2016 | 558755000000 | 72700000 |
| Sunday, January 1, 2017 | 495921000000 | 105700000 |
| Monday, January 1, 2018 | 659690000000 | 198700000 |
| Tuesday, January 1, 2019 | 1089764000000 | 117600000 |
| Wednesday, January 1, 2020 | 994308000000 | 108100000 |
| Friday, January 1, 2021 | 1106846000000 | 122500000 |
| Saturday, January 1, 2022 | 1244072000000 | 146700000 |
| Sunday, January 1, 2023 | 1431505000000 | 257500000 |
| Monday, January 1, 2024 | 1431505000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Takeda Pharmaceutical Company Limited and United Therapeutics Corporation, two industry titans, have shown contrasting trends in their cost of revenue from 2014 to 2023. Takeda's cost of revenue has surged by approximately 175% over this period, peaking in 2023. This growth reflects Takeda's aggressive expansion and investment strategies. In contrast, United Therapeutics has maintained a more stable cost structure, with a modest increase of around 105% over the same period. This stability suggests a focus on efficiency and cost management. Notably, data for 2024 is incomplete, highlighting the need for ongoing analysis. These trends offer valuable insights into the strategic priorities of these companies and underscore the diverse approaches within the pharmaceutical sector.
Cost of Revenue Comparison: AbbVie Inc. vs United Therapeutics Corporation
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and United Therapeutics Corporation
Analyzing Cost of Revenue: Takeda Pharmaceutical Company Limited and Cytokinetics, Incorporated
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Agios Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited vs United Therapeutics Corporation: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down United Therapeutics Corporation and Alkermes plc's Expenses
Cost of Revenue Trends: United Therapeutics Corporation vs PTC Therapeutics, Inc.
Cost of Revenue Trends: United Therapeutics Corporation vs HUTCHMED (China) Limited